Delgocitinib US Patent Status
The primary US patent for delgocitinib is US Patent No. 10,570,283 [1]. This patent is held by Anacor Pharmaceuticals, Inc. [1].
When Does Delgocitinib's US Patent Expire?
The expected expiry date for US Patent No. 10,570,283, covering delgocitinib, is March 20, 2032 [1]. This date accounts for potential patent term adjustments [1].
What Does Delgocitinib's Patent Protect?
The patent for delgocitinib, US Patent No. 10,570,283, primarily claims the compound itself [1]. This means it protects the chemical entity of delgocitinib [1].
Are There Other Patents Related to Delgocitinib?
Beyond the core compound patent, there are other related patents and patent applications associated with delgocitinib. DrugPatentWatch.com lists numerous patents and applications that may cover various aspects, such as specific formulations, methods of use, or manufacturing processes for delgocitinib [2]. These can include patents filed by Anacor Pharmaceuticals and its subsequent parent companies, such as Pfizer [2].
Who Owns the Delgocitinib Patent?
Anacor Pharmaceuticals, Inc. initially held the US patent for delgocitinib [1]. Following Anacor's acquisition, ownership and related intellectual property rights would have transferred to its acquiring entity, which is now part of Pfizer [2].
What is the Significance of Delgocitinib?
Delgocitinib is a Janus kinase (JAK) inhibitor [3]. It is being developed for the treatment of various inflammatory conditions, including atopic dermatitis [3]. The drug targets specific signaling pathways involved in the inflammatory response [3].
What is the Competition for Delgocitinib?
As a JAK inhibitor, delgocitinib competes in a therapeutic area with other drugs that also target the JAK pathway. These competitors include other JAK inhibitors approved or in development for similar inflammatory conditions [3]. The market for treatments of atopic dermatitis, for example, includes other topical and systemic therapies [3].